Spyre Therapeutics, Inc. (SYRE)
92.42
+2.18
(+2.41%)
USD |
NASDAQ |
Sep 21, 09:59
Spyre Therapeutics Total Long Term Debt (Quarterly) : 0.00 for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.00 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 253.40M |
| December 31, 2023 | 84.56M |
| September 30, 2023 | 387.10M |
| June 30, 2023 | 197.32M |
| March 31, 2023 | 3.823M |
| December 31, 2022 | 4.02M |
| September 30, 2022 | 4.159M |
| June 30, 2022 | 4.316M |
| March 31, 2022 | 4.475M |
| December 31, 2021 | 5.042M |
| September 30, 2021 | 4.746M |
| June 30, 2021 | 4.88M |
| March 31, 2021 | 5.009M |
| December 31, 2020 | 5.201M |
| September 30, 2020 | 4.947M |
| Date | Value |
|---|---|
| June 30, 2020 | 4.695M |
| March 31, 2020 | 4.815M |
| December 31, 2019 | 4.771M |
| September 30, 2019 | 4.933M |
| June 30, 2019 | 4.887M |
| March 31, 2019 | 0.45M |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| AbbVie, Inc. | 70.82B |
| Incyte Corp. | 32.68M |
| SELLAS Life Sciences Group, Inc. | 0.157M |
| BridgeBio Pharma, Inc. | 3.370B |
| Relay Therapeutics, Inc. | 26.64M |